Menu
Recruiting NCT04098133

Epidemiology of Carbapenemase-producing Bacteria in a Swiss Tertiary Care Hospital

— Observational Infections With CPB

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: data collection for demographic data, data collection for clinical data, data collection for treatment data, data collection for microbiological data.
Who it may be relevant to
Registry conditions: Infections With CPB. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Switzerland
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

This retrospective and prospective study is to investigate the incidence of Carbapenemase-producing bacteria (CPB) at the University Hospital Basel, the time to detection of CPB and to initiation of infection control measures, the risk factors associated with carriage of CPB, type and duration of previously administrated antibiotic medication, antibiotic treatment, as well as to assess the outcomes of the affected patients.

Interventions

  • Other data collection for demographic data
    data collection for demographic data (age, gender, hospital admission and discharge date, length of stay, hospitalization prior to current hospital stay (acute care facilities, long-term healthcare centres, nursing homes), discharge destination, outcome, cause of death, travel history, previous exposure to antibiotics and proton pump Inhibitors)
  • Other data collection for clinical data
    data collection for clinical data (comorbidities, Charlson Comorbidity Index, immunosuppressive treatment, date of diagnosis of CPB, days between hospital admission and diagnosis of CPB, type of consecutive infection, indwelling vascular hardware, urinary catheterization, surgical therapies)
  • Other data collection for treatment data
    data collection for treatment data (antibiotic therapy, immunosuppressive therapy, concomitant medication)
  • Other data collection for microbiological data
    data collection for microbiological data (species of CPB, type of sample, date of sample, history of colonization or infection with any antibiotic resistant pathogen)

Primary outcome measures

  • incidence of CPB at the University Hospital Basel (number) [Time frame: from January 1st , 2008 until December 31st, 2028]
Secondary outcome measures (9)
  • time to detection of CPB (days) [Time frame: from January 1st , 2008 until December 31st, 2028]
  • time to initiation of infection control measures [Time frame: from January 1st , 2008 until December 31st, 2028]
  • time to adequate treatment in patients with CPB infections [Time frame: from January 1st , 2008 until December 31st, 2028]
  • presence of established risk factors for CPB [Time frame: from January 1st , 2008 until December 31st, 2028]
  • length of hospital stay (days) [Time frame: from January 1st , 2008 until December 31st, 2028]
  • discharge destination [Time frame: from January 1st , 2008 until December 31st, 2028]
  • cure from infection [Time frame: from January 1st , 2008 until December 31st, 2028]
  • cause-specific mortality (number) [Time frame: from January 1st , 2008 until December 31st, 2028]
  • all-cause mortality (number) [Time frame: from January 1st , 2008 until December 31st, 2028]

Eligibility criteria

Inclusion criteria

  • Patients with detection of carbapenemase-producing bacteria from January 1st , 2008 until December 31st , 2028

Exclusion criteria

  • Patients with documented refusal of subsequent use of their data

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

Switzerland · 1 center
  • Division of Infectious Diseases and Hospital Epidemiology — Basel

Identifiers

NCT: NCT04098133 · 2019-01548; me19Tschudinsutter

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗